Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SLAM DRILLS MORE COPPER MINERALIZATION AT GOODWIN (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Regenxbio Inc RGNX

Healthcare Biotechnology
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three... see more

Recent & Breaking News (NDAQ:RGNX)

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire June 9, 2021

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at American Society of Gene and Cell Therapy's 24th Annual Meeting

PR Newswire May 14, 2021

REGENXBIO to Present at Upcoming Investor Conferences

PR Newswire May 6, 2021

REGENXBIO Reports First Quarter 2021 Financial Results and Operational Highlights

PR Newswire May 5, 2021

REGENXBIO to Host Conference Call on May 5 to Discuss First Quarter 2021 Financial Results and Recent Operational Highlights

PR Newswire April 28, 2021

REGENXBIO Announces Presentations at the American Society of Gene and Cell Therapy's 24th Annual Meeting

PR Newswire April 27, 2021

REGENXBIO To Present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit

PR Newswire April 21, 2021

REGENXBIO Announces Dosing of First Patient in Cohort 3 of Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome)

PR Newswire April 14, 2021

REGENXBIO Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights

PR Newswire March 1, 2021

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire February 24, 2021

REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights

PR Newswire February 22, 2021

REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD

PR Newswire February 16, 2021

REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 17th Annual WORLDSymposium(TM) 2021

PR Newswire February 8, 2021

REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2021 Conference

PR Newswire February 5, 2021

REGENXBIO Announces Presentations at the 17th Annual WORLDSymposium(TM) 2021

PR Newswire February 1, 2021

REGENXBIO Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

PR Newswire January 12, 2021

REGENXBIO to Present at the 39th Annual J.P. Morgan Healthcare Conference

PR Newswire January 11, 2021

REGENXBIO Announces Pricing Of Public Offering Of Common Stock

PR Newswire January 8, 2021

REGENXBIO Announces Proposed Public Offering Of Common Stock

PR Newswire January 6, 2021

REGENXBIO Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD and New Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy

PR Newswire January 5, 2021